Study details
Enrolling now
Lenrispodun Trial for Parkinson's Disease
Intra-Cellular Therapies, Inc.
NCT IDNCT05766813ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
132
Study length
about 2.6 years
Ages
40+
Locations
31 sites in AZ, CA, FL +11
What this study is about
This trial is testing Lenrispodun as an add-on treatment for people with Parkinson's disease who have motor fluctuations. Participants will be randomly assigned to receive either Lenrispodun or a placebo (inactive pill). It lasts 963 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lenrispodun
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Body systems
Neurology